AlergoMax (dimethynden maleat) syrup 100 ml.

active ingredient: 1 ml of the drug contains desloratadine 0.5 mg;
excipients: sodium benzoate (E 211) trilon B; citric acid; sodium; flavoring “Strawberry” containing propylene glycol, aromatic substances (natural, identical to natural) dye Sunset Yellow FCF (E 110) propylene glycol; sorbitol (E 420) sucrose; purified water.

Antihistamines for systemic use.
ATX code R06A X27.

Desloratadine is a potent selective blocker of peripheral H1 receptors that does not have a sedative effect. Desloratadine is the primary active metabolite of loratadine.
After administration, the drug selectively blocks peripheral H1-histamine receptors, since it almost does not penetrate the blood-brain barrier.
In addition to antihistamine activity, the drug has anti-allergic and anti-inflammatory effects.

It has been established that the drug suppresses a cascade of various reactions that underlie the development of allergic inflammation, namely:

• release of pro-inflammatory cytokines, including IL-4, IL-6, IL-8, IL-13;
• release of pro-inflammatory chemokines such as RANTES;
• production of superoxide anion by activated polymorphonuclear neutrophils;
• adhesion and chemotaxis of eosinophils;
• expression of adhesion molecules such as P-selectin;
• IgE-dependent release of histamine, prostaglandin D2 and leukotriene C4;
• acute allergic bronchospasm and allergic cough in animals.

There is evidence that treatment with desloratadine in children was well tolerated, as evidenced by clinical laboratory results, vital signs, and ECG data (including QT interval length).
Daily use of desloratadine at a dose of up to 20 mg for 14 days was not accompanied by statistically clinically significant changes in the cardiovascular system. The use of desloratadine 45 mg/day (9 times higher than the therapeutic dose) for 10 days did not cause prolongation of the QT interval.
Desloratadine almost does not penetrate the blood-brain barrier. When using the recommended dose of 5 mg, the frequency of drowsiness did not exceed that in individuals, desloratadine was not used. Desloratadine did not affect psychomotor function at doses up to 7.5 mg.
In addition to the accepted division of allergic rhinitis into seasonal and year-round, according to the duration of symptoms, allergic rhinitis can alternatively be classified into intermittent and persistent. Intermittent allergic rhinitis is defined as the presence of symptoms for less than 4 days per week or less than 4 weeks. In the case of persistent allergic rhinitis, symptoms occur for 4 days or more per week or for a period longer than 4 weeks.
The drug is effective in the treatment of seasonal allergic rhinitis; in patients with allergic rhinitis, desloratadine effectively eliminates such symptoms: sneezing, nasal discharge and itching, as well as eye irritation, tearing and redness, and itching of the palate.

To relieve symptoms associated with allergic rhinitis such as sneezing, nasal discharge, itching, swelling and nasal congestion, as well as itchy and red eyes, watery eyes, itchy palate and coughing.
To relieve symptoms associated with hives, such as itching and rashes.

Hypersensitivity to desloratadine, to any auxiliary component of the drug or to loratadine.

The drug enhances the effects of alcohol, such as impaired psychomotor function and drowsiness. The results of psychomotor tests did not differ significantly between patients treated with desloratadine and patients who did not use it, alone or with alcohol.
In patients with severe renal insufficiency, the drug should be administered under medical supervision.
Sunset Yellow dye may cause allergic reactions.
If the patient has an intolerance to some sugars, a doctor should be consulted before taking this drug.
Desloratadine should be used with caution in patients with a history of seizures. Children may be more susceptible to developing a new seizure when treated with desloratadine. The physician should decide to discontinue treatment with desloratadine in patients who experience seizures while using the drug.

To eliminate the symptoms associated with allergic rhinitis (including intermittent and persistent) and urticaria, the drug is used regardless of food intake in the following doses: adults and adolescents (³ 12 years) 10 ml syrup (5 mg desloratadine) 1 time per day day.
Therapy for intermittent allergic rhinitis (presence of symptoms less than 4 days per week or less than 4 weeks) should be carried out taking into account the data of the anamnesis: stop after the disappearance of symptoms and restore after their reappearance. With persistent allergic rhinitis (presence of symptoms more than 4 days a week or more than 4 weeks), it is necessary to continue treatment during the entire period of contact with the allergen.

The efficacy and safety of the drug in children under the age of 6 months have not been established. The drug is not recommended for children under 6 months of age for the treatment of chronic idiopathic urticaria and for children under 12 months of age for the treatment of allergic rhinitis.

For treatment, the following dosing regimen is used:

• at the age of 6 to 11 months, 2 ml of syrup (1 mg of desloratadine) 1 time per day;
• at the age of 1 to 5 years, 2.5 ml of syrup (1.25 mg of desloratadine) 1 time per day;
• at the age of 6 to 11 years: 5 ml of syrup (2.5 mg of desloratadine) 1 time per day.